Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The endothelin receptor antagonist bosentan has been shown to improve exercise tolerance, hemodynamics, and clinical deterioration in trials of patients with advanced symptoms due to pulmonary hypertension (WHO functional class III and IV).

Bosentan for Early Pulmonary Hypertension